| Market Capitalization (Millions $) |
405 |
| Shares
Outstanding (Millions) |
65 |
| Employees |
72 |
| Revenues (TTM) (Millions $) |
26 |
| Net Income (TTM) (Millions $) |
-339 |
| Cash Flow (TTM) (Millions $) |
121 |
| Capital Exp. (TTM) (Millions $) |
1 |
Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc. is a biopharmaceutical company that focuses entirely on the development and commercialization of treatments for gastrointestinal diseases. The company was founded in 2018 and is headquartered in Buffalo Grove, Illinois. The company aims to improve the lives of patients suffering from gastrointestinal diseases, which are often challenging to diagnose and treat.
Phathom is driven by its mission to provide innovative treatments and medical solutions, which are based on deep scientific and clinical understanding of gastrointestinal diseases. The company's expertise is demonstrated by its current product portfolio, which includes two FDA-approved treatments for gastrointestinal diseases.
The first product, Omeprazole Magnesium-antazoline Sodium, is a combination therapy for the treatment of gastroesophageal reflux disease (GERD) and other acid-related conditions. This product is intended for patients who are unresponsive to conventional treatment options. The second product, Vonoprazan, is a proton pump inhibitor (PPI) that is used to treat GERD and for the prevention of gastric ulcers. Both products are highly effective and have helped many patients manage their symptoms and improve their quality of life.
In addition to its existing product portfolio, Phathom is also investing in the development of novel treatments for gastrointestinal diseases. The company has a deep pipeline of potential treatments that are currently in various stages of development, including treatments for Helicobacter pylori infection and eosinophilic esophagitis. The company's pipeline is highly promising, and many of its potential treatments have shown promising results in clinical trials.
Phathom has a highly experienced and skilled management team that is led by Dr. Azmi Nabulsi, who serves as the CEO. The company also has a strong group of investors, including leading venture capital firms and institutional investors. With its deep scientific understanding of gastrointestinal diseases, strong product portfolio, and promising pipeline, Phathom Pharmaceuticals Inc has established itself as a leading player in the pharmaceutical industry for the treatment of gastrointestinal diseases.
Company Address: 100 Campus Drive Florham Park 7932 NJ
Company Phone Number: 742-8466 Stock Exchange / Ticker: NASDAQ PHAT
|
0.09% 
100.29 %